A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with Moderate to Severe COPD

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with Moderate to Severe COPD

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2011

At a glance

  • Drugs AZD 9056 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 May 2011 This trial is recruiting in Great Britain and has completed in Hungary and the Sweden.
    • 12 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top